FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3150586614> ?p ?o ?g. }

• W3150586614 abstract "<h3>Background</h3> Injecting drug use accounts for ~90% of HCV infections in the UK. Needle and Syringe Programs (NSPs) present a key opportunity for early detection of incident HCV infection in active injectors. Despite this, there are no clear pathways for this vulnerable group. Our aim was to establish a defined blood-borne virus (BBV) testing pathway for people accessing NSPs co-located with drug treatment services (DTS) and streamline care for clients diagnosed with HCV. <h3>Description of Model of Care/Intervention</h3> We commissioned a behavioural science research group to conduct an observational study at three NSP sites to map pathways and identify barriers to BBV testing and linkage-to-care (LTC). These outputs informed our multidisciplinary steering committee, consisting of the HCV treatment delivery network, CGL (DTS provider), local NSP staff and Gilead. We agreed an optimised BBV pathway to integrate HCV clinical assessment and treatment into harm reduction within the NSP. We then launched a multifaceted campaign including bespoke training, data support, peer mentorship and disease awareness materials. <h3>Effectiveness</h3> Prior to this initiative, BBV testing was ad-hoc and data capture was not required. The project is currently ongoing; 6-month snapshot analysis (Feb2020): 732 unique clients attended NSP 100% (n=732) offered a BBV test 22% (162/732) accepted 41% (66/162) HCV antibody positive 20% (33/162) HCV PCR positive 75% (25/33) referred to the on–site hepatology clinic 24% (8/33) started and 6% (2/33) completed treatment <h3>Conclusion</h3> Integrated NSP-BBV pathways will be crucial to eliminate HCV given the high prevalence observed. Linkage to care is ongoing; however, to-date, we have successfully initiated therapy in 8 patients at risk of onward transmission. The early data suggest testing uptake in this group is challenging. Phase 2 is focusing on increasing uptake of BBV testing and increasing linkage to treatment within the NSP. <h3>Disclosure of Interest Statement</h3> The observational study, CGL coordinators and data analyst were funded by Gilead Sciences as part of the NHS England HCV Elimination Programme." @default.
• W3150586614 created "2021-04-13" @default.
• W3150586614 creator A5001954438 @default.
• W3150586614 creator A5036306772 @default.
• W3150586614 creator A5064423266 @default.
• W3150586614 creator A5065512477 @default.
• W3150586614 creator A5072310535 @default.
• W3150586614 creator A5081454478 @default.
• W3150586614 creator A5089742776 @default.
• W3150586614 date "2020-09-01" @default.
• W3150586614 modified "2023-10-14" @default.
• W3150586614 title "P69 NEXIT: Needle exchange initiative targeting hepatitis C (HCV) incidence in people who inject drugs (PWID) – phase 1" @default.
• W3150586614 doi "https://doi.org/10.1136/gutjnl-2020-basl.79" @default.
• W3150586614 hasPublicationYear "2020" @default.
• W3150586614 type Work @default.
• W3150586614 sameAs 3150586614 @default.
• W3150586614 citedByCount "0" @default.
• W3150586614 crossrefType "proceedings-article" @default.
• W3150586614 hasAuthorship W3150586614A5001954438 @default.
• W3150586614 hasAuthorship W3150586614A5036306772 @default.
• W3150586614 hasAuthorship W3150586614A5064423266 @default.
• W3150586614 hasAuthorship W3150586614A5065512477 @default.
• W3150586614 hasAuthorship W3150586614A5072310535 @default.
• W3150586614 hasAuthorship W3150586614A5081454478 @default.
• W3150586614 hasAuthorship W3150586614A5089742776 @default.
• W3150586614 hasBestOaLocation W31505866141 @default.
• W3150586614 hasConcept C104863432 @default.
• W3150586614 hasConcept C126322002 @default.
• W3150586614 hasConcept C138816342 @default.
• W3150586614 hasConcept C159110408 @default.
• W3150586614 hasConcept C2776455275 @default.
• W3150586614 hasConcept C512399662 @default.
• W3150586614 hasConcept C71924100 @default.
• W3150586614 hasConceptScore W3150586614C104863432 @default.
• W3150586614 hasConceptScore W3150586614C126322002 @default.
• W3150586614 hasConceptScore W3150586614C138816342 @default.
• W3150586614 hasConceptScore W3150586614C159110408 @default.
• W3150586614 hasConceptScore W3150586614C2776455275 @default.
• W3150586614 hasConceptScore W3150586614C512399662 @default.
• W3150586614 hasConceptScore W3150586614C71924100 @default.
• W3150586614 hasLocation W31505866141 @default.
• W3150586614 hasOpenAccess W3150586614 @default.
• W3150586614 hasPrimaryLocation W31505866141 @default.
• W3150586614 hasRelatedWork W150703042 @default.
• W3150586614 hasRelatedWork W1878781068 @default.
• W3150586614 hasRelatedWork W2011874314 @default.
• W3150586614 hasRelatedWork W2022520514 @default.
• W3150586614 hasRelatedWork W2129374379 @default.
• W3150586614 hasRelatedWork W2410837653 @default.
• W3150586614 hasRelatedWork W2954475304 @default.
• W3150586614 hasRelatedWork W2996474769 @default.
• W3150586614 hasRelatedWork W4255793139 @default.
• W3150586614 hasRelatedWork W4377861290 @default.
• W3150586614 isParatext "false" @default.
• W3150586614 isRetracted "false" @default.
• W3150586614 magId "3150586614" @default.
• W3150586614 workType "article" @default.